Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation

Annemarie Weissenbacher, Claudia Boesmueller, Gerald Brandacher, Robert Oellinger, Johann Pratschke, Stefan Schneeberger

Research output: Contribution to journalReview articlepeer-review

Abstract

Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literature on alemtuzumab in solid organ and composite tissue allotransplantation with an emphasis on clinical and mechanistic aspects of alemtuzumab. In summary, the use of alemtuzumab in solid organ and composite tissue allotransplantation shows excellent early results and holds potential for wider use in conjunction with immunosuppression minimization protocols.

Original languageEnglish (US)
Pages (from-to)783-790
Number of pages8
JournalImmunotherapy
Volume2
Issue number6
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

Keywords

  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation'. Together they form a unique fingerprint.

Cite this